At the completion of this educational session, learners will:
- Know about new interferon-free and interferon-sparing HCV regimens in development.
- Understand results from HCV treatment trials in HIV-HCV coinfected patients.
- Be aware of HCV treatment trials for HIV-HCV coinfected patients in NYC.
Tracy Swan has been involved with HIV-related work since 1990 and hepatitis C virus since 1998. Before joining Treatment Action Group (TAG) in 2003, Ms. Swan worked at homeless shelters, in-and out-patient drug treatment programs, syringe exchange programs, methadone clinics, a drop in center for gay, lesbian, transgender and bisexual youth, hospitals and clinics. Ms. Swan is currently the Hepatitis/HIV Project Director at TAG, where she advocates for broad and inclusive hepatitis C research and promotes policies to increase access to and quality of care for HCV monoinfected and HIV/HCV coinfected persons. Ms Swan works domestically and internationally, with people living with or at risk for HIV and HCV, activists and advocates, harm reductionists, researchers, clinicians, and pharmaceutical companies; she has been a Consumer Representative on the FDA Antiviral Advisory Committee and has served as a Community Representative on the AIDS Clinical Trials Group. Ms. Swan is a co-founder and coordinator of the Hepatitis C Community Advisory Board (HCAB), an international group of treatment activists focused on HCV drug development.
To obtain CME credit for this and other PRN programs, please visit the PRN Video Channel
at the Clinical Education Initiative (CEI) web site http://www.ceitraining.org/prn-video/. PRN and the Medical Society of the State of New York (MSSNY) jointly sponsor PRN enduring materials for CME, and provide them at no cost to the AIDS Institute of the New York State Department of Health (NYSDOH) for broadcast through the CEI. We thank the NYSDOH for making our CME programs available to a wider audience, and hope you will also browse the many other educational opportunities offered by the CEI.